Literature DB >> 2411797

Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2.

J E Talmadge, R B Herberman, M A Chirigos, A E Maluish, M A Schneider, J S Adams, H Philips, G B Thurman, L Varesio, C Long.   

Abstract

Augmentation of natural killer (NK) cell activity has been observed after the single administration of a wide variety of biological response modifiers (BRM); however, multiple injections of BRM have resulted in hyporesponsiveness to NK augmentation in both preclinical and clinical studies. In these studies, hyporesponsiveness to augmentation of NK cell activity occurred after multiple injections of interferon (IFN recombinant human IFN-alpha A/D and recombinant IFN-gamma) and interleukin 2 and was found to be systemic (lungs, liver, blood, and spleen). In contrast, hyporesponsiveness to augmentation by multiple injections of maleicanhydride divinyl ether (MVE-2) or Propionibacterium acnes was limited to the spleen and peripheral blood lymphocytes, with continued augmentation of NK cell activity in the peritoneum, lungs, and liver. Despite the hyporesponsiveness to augmentation of NK activity by multiple IFN injections, NK activity could still be augmented by a single injection of another BRM. The NK cell hyporesponsiveness induced in the spleen by MVE-2 was also reversed by a single administration of IFN or polyinosinic-polycytidylic and poly-L-lysine solubilized by carboxymethyl cellulose but not by OK-432 or P. acnes. These results demonstrate that the nature of the hyporesponsiveness to NK augmentation, which is induced by multiple treatments with BRM, varies with the type of agent. The noncytokine BRM that were studied induced hyporesponsiveness only in specific lymphoid compartments but not in major nonlymphoid organs, whereas cytokine BRM induced a systemic hyporesponsiveness. The hyporesponsive state induced by the different types of BRM, also varied in regard to the pattern of susceptibility to augmentation of NK activity by unrelated BRM.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2411797

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes.

Authors:  Kutlu G Elpek; Mark P Rubinstein; Angelique Bellemare-Pelletier; Ananda W Goldrath; Shannon J Turley
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

2.  Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid.

Authors:  A E Lee; L A Rogers; J M Longcroft; R E Jeffery
Journal:  Clin Exp Metastasis       Date:  1990 Mar-Apr       Impact factor: 5.150

3.  Pathogenesis of Cryptococcus neoformans in congenitally immunodeficient beige athymic mice.

Authors:  C A Salkowski; E Balish
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

4.  Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy.

Authors:  A Eisenthal; Y Skornick; I Ron; V Zakuth; S Chaitchik
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

5.  A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.

Authors:  Nicholas Butowski; Kathleen R Lamborn; Bee L Lee; Michael D Prados; Timothy Cloughesy; Lisa M DeAngelis; Lauren Abrey; Karen Fink; Frank Lieberman; Minesh Mehta; H Ian Robins; Larry Junck; Andres M Salazar; Susan M Chang
Journal:  J Neurooncol       Date:  2008-10-11       Impact factor: 4.130

6.  Role of natural killer cells in infection with the mouse pneumonitis agent (murine Chlamydia trachomatis).

Authors:  D M Williams; J Schachter; B Grubbs
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

7.  Augmentation of natural cell activity in tumor-bearing and normal mice by MVE-2.

Authors:  W Budzynski; M Chirigos; E Gruys
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  IFN-treatment of B16-F1 versus B16-F10: relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spread.

Authors:  M Zöller
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

9.  Stimulation of natural killer cytotoxicity by long-term treatment with double-stranded polynucleotides without induction of hyporesponsiveness.

Authors:  D Nolibe; M N Thang
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

10.  A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).

Authors:  Nicholas Butowski; Susan M Chang; Larry Junck; Lisa M DeAngelis; Lauren Abrey; Karen Fink; Tim Cloughesy; Kathleen R Lamborn; Andres M Salazar; Michael D Prados
Journal:  J Neurooncol       Date:  2008-09-17       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.